1. |
Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy:a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int, 2006, 69(11):1945-1953.
|
2. |
陈玉琼, 王美云.血液灌流联合血液透析治疗尿毒症顽固性皮肤瘙痒.江苏大学学报:医学版, 2007, 17(4):338-339.
|
3. |
《活性维生素D的合理应用》专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识.中华肾脏病杂志, 2005, 21(11):698-699.
|
4. |
Malberti F. Management of hyperphosphatemia in dialysis patients: the role of phosphate binders. G Ital Nefrol, 2010, 27(Suppl 52):47-54.
|
5. |
Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol, 2004, 15(12):2959-2964.
|
6. |
Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease:results of the study to evaluate early kidney disease. Kidney Int, 2007, 71(1):31-38.
|
7. |
Martinez I, Saracho R, Montenegro J, et al. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis, 1997, 29(3): 496-502.
|
8. |
孙志宏, 安惠霞, 杨霞.慢性肾衰血透患者甲状旁腺激素与营养的关系研究.哈尔滨医科大学学报, 2008, 42(5):485-487.
|
9. |
Feldman D, Sampson JN, Rudser KD, et al. Treatment of secondary hyperparathyroidism in patients with chronic renal failure maintained on hemodialysis (CKD stage 5). Endocrinologia J, 1986, 32(6): 863-874.
|
10. |
Ishida M, Yao N, Yachiku S, et al. Management of calcium, phosphorus and bone metalbolian in dialysis patients using sevelamer hydrochloride and vitamin D therapy. Ther Apher Dial, 2005, 9(Suppl 1):16-21.
|
11. |
Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant, 2007, 22(3):2909-2916.
|
12. |
Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysi. J Am Soc Nephrol, 2004, 15(3):2208-2218.
|
13. |
Coladonato JA, Szczech L, Friedman EA, et al. Does calcium kill ESRD patients? The skeptic, s perspective. Nephrol Dial Transplant, 2002, 17(2):229-232.
|
14. |
Toida T, Fukudome K, Fujimoto S, et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients:a crossover study. Clin Nephrol, 2012, 3(2):216-223.
|
15. |
Joy MS, Finn WF. Result of a randomized phase Ⅲ dosetitrating, parallel group study of 1anthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients. J Am Soc Nephrol, 2001, 12:388A.
|
16. |
Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia:a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract, 2005, 100(1):c8-c19.
|
17. |
Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum Carbonate:Results from a 3-Year Study. Nephron Clin Pract, 2006, 102(1):c61-c71.
|
18. |
Daugirdas JT, Finn WF, Emmett M, et al. The phosphate binder equivalent dose. Semin Dial, 2011, 21(1):41-49.
|